Tasimelteon inhibits glioma proliferation by inducing ferroptosis via the SP1/ACSL4 pathway Authors: Yi Chen, Jicheng Li, Huilan Yang, Haiyang Liang, Ji Shi, Quan Li, Qiang Liu, Jia Liu, Xuanming Zhang, Huizhe Xu, Haozhe Piao Published: 2026 ABSTRACT AbstractPurposeGliomas are aggressive tumors with poor treatment outcomes. Tasimelteon, an FDA-approved melatonin receptor agonist with favorable blood-brain barrier penetration, has unexplored anti-tumor potential. This study investigated whether Tasimelteon inhibits glioma proliferation through ferroptosis induction.MethodsCell viability, colony formation, and immunofluorescence were employed to assess the effects of Tasimelteon on glioma cells. Ferroptosis was assessed by measuring lipid peroxidation markers (MDA, 4-HNE, BODIPY 581/591 C11) and ROS levels, and mitochondrial damage was detected by TEM. Mechanisms were examined through Western blotting, qPCR, dual-luciferase reporter assays, site-directed mutagenesis and molecular docking. In vivo, LN229-Luc glioma cells were orthotopically injected into mouse brains, followed by Tasimelteon treatment. Tumor growth was monitored by bioluminescence imaging, and body weight and survival were recorded. Systemic toxicity was evaluated through H&E staining of major organs.ResultsTasimelteon decreased glioma cell viability and colony formation in dose- and time-dependent manners. Mechanistically, Tasimelteon induced ferroptosis, characterized by elevated lipid peroxidation markers (MDA, 4-HNE) and ROS levels, along with mitochondrial damage observed by TEM. This process was accompanied by ACSL4 upregulation. Further investigation revealed that Tasimelteon bound to SP1 at Gln465 and Leu467 residues, stabilizing the protein and enhancing ACSL4 transcription, independent of MT1/MT2 receptor activation. In orthotopic glioma models, Tasimelteon suppressed tumor growth by inducing ferroptosis and prolonged survival without systemic toxicity.ConclusionTasimelteon inhibits glioma growth by inducing ferroptosis via the SP1/ACSL4 pathway, offering a novel therapeutic approach.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s13402-026-01244-z.Keywords: Tasimelteon, Glioma, Ferroptosis, Lipid peroxidation, ACSL4, SP1 Introduction Gliomas, originating from neuroglial and neural precursor cells, are the most common primary intracranial tumors [1]. Their annual incidence has risen over the past 30 years [2], with a global rate of approximately 6 per 100,000 people [3]. According to the 2021 WHO Classification of Tumors of the Central Nervous System, gliomas are now classified by integrating histological features with key molecular markers such as IDH mutation and 1p/19q codeletion, highlighting their substantial molecular heterogeneity [4]. Despite treatment advances, the median survival for high-grade gliomas remains low due to complex biology, molecular heterogeneity, and poor blood-brain barrier (BBB) penetration [5]. Although emerging modalities such as immunotherapy [6] and nanomedicine-based drug delivery like engineered RAP-anchored copper-escorting liposomes [7] have been explored in glioblastoma, overall prognosis remains discouraging with a 5-year survival rate below 10% [8]. Melatonin (N-acetyl-5-methoxytryptamine), secreted by the pineal gland, regulates circadian rhythms and diverse physiological functions [9, 10]. Beyond its antioxidant and anti-inflammatory roles, melatonin exhibits tumor-suppressive effects in various cancers, including glioblastoma [11, 12], through diverse mechanisms involving antioxidative, antiproliferative, pro-apoptotic, and antiangiogenic actions [13]. However, melatonin’s clinical utility is limited by short half-life (~ 30 min), low blood-brain barrier permeability, and potential endocrine interference [14]. Tasimelteon as a melatonin receptor agonist exhibits higher MT2 selectivity, superior blood-brain barrier permeability, a longer half-life, and minimal pituitary impact on pituitary function compared to melatonin [15–17]. While explored for sleep and neuropsychiatric disorders, its anti-tumor potential remains largely unknown. Ferroptosis is an iron-dependent form of programmed cell death characterized by lipid peroxide accumulation [18, 19], involving mitochondrial shrinkage and increased membrane density [20]. The mechanism is closely linked to iron metabolism, lipid peroxidation, and antioxidant systems [21], notably the SLC7A11-GPX4 axis [22–24]. Cancer cells are particularly susceptible to ferroptosis due to their high iron demands [25]. Moreover, the brain’s high concentration of polyunsaturated fatty acids makes gliomas especially sensitive to ferroptosis [26]. While molecules like Erastin and sorafenib induce ferroptosis in brain tumors, triggering this pathway remains a promising research frontier. This study demonstrates, for the first time, that Tasimelteon inhibits glioma proliferation both in vitro and in vivo. Mechanistically, Tasimelteon induces ferroptosis via ACSL4 upregulation, driven by the enhanced binding of transcription factor SP1 to the ACSL4 promoter independently of MT1/MT2 receptor activation. Our findings provide a novel therapeutic perspective for glioma treatment. Methods Cells, plasmids, reagents and antibodies Human glioblastoma LN229, A172 and human microglial HMC cell lines were obtained from the American Type Culture Collection (ATCC, USA). LN229 cells harbor TP53 mutation, wild-type PTEN, IDH-wildtype status and homozygous CDKN2A/B deletion; A172 cells retain wild-type TP53 but exhibit PTEN loss/mutation, IDH-wildtype status, and high-molecular-weight EGFR expression [27] with mesenchymal features according to CCLE (https://depmap.org/portal/ccle/) and COSMIC (https://cancer.sanger.ac.uk/cosmic/) database. The patient-derived glioblastoma cells GBM1492 were a gift from Dr. Zhiyou Fang, Hefei Institutes of Physical Science, Chinese Academy of Sciences. SP1 and ACSL4 cDNA were obtained from Miaoling Biotechnology (Wuhan, China). Mutations of SP1 with Flag tag were constructed by standard molecular cloning procedures. siControl and siACSL4 were designed by Genepharma (Shanghai, China). GoldenTran®-R (Golden Trans Technology, Changchun, China) was used for transfection. Several chemical inhibitors were employed in this study, including 4-P-PDOT (MCE, HY-100609), BAPTA-AM (MCE, HY-100545), BODIPY 581/591 C11 (Dojindo, L267), Chloroquine (Selleck, S6999), Doxorubicin (Selleck, S1208), Erastin (MCE, HY-15763), Ferrostatin-1 (Selleck, S7243), Liproxstatin-1 (Selleck, S7699), Mdivi-1 (Selleck, S7162), Melatonin (MCE, HY-B0075), Necrostatin-1 (Selleck, S8037), S26131 (MCE, HY-122136), Tasimelteon (Selleck, S4281), Z-VAD-FMK (Selleck, S7023). The following kits and reagents were used for various assays: cAMP ELISA KIT (Elabscience, E-EL-0056), CCK-8 kit (MCE, HY-K0301-3000T), Lipid Peroxidation (MDA) Assay Kit (Sigma-Aldrich, MAK085), SYTOX Green Nucleic Acid Stain (Invitrogen, S7020), and BCA Protein Assay Kit (Beyotime, P0012). For immunoblotting and immunofluorescence, the following antibodies were used: TFRC (Invitrogen, 13-6800), ACSL4 (Abcam, ab155282), DMT1 (Proteintech, 20507-1-AP), FTH1 (CST, 4393 S), NCOA4 (Abcam, ab62495), NRF2 (Proteintech, 16396-1-AP), FSP1 (Proteintech, 20886-1-AP), DHODH (Proteintech, 14877-1-AP), GPX4 (Abcam, ab125066), SLC7A11 (CST, 12691 S), GAPDH (Huabio, ET1601-4), SP1 (Santa Cruz, SC-420), A20 (Santa Cruz, SC-166692), YAP (Novus, NB110-58358), SHP2 (Santa Cruz, SC-7384), Rabbit IgG-HRP (Huabio, HA1001), Mouse IgG-HRP (Huabio, HA1006), Alexa Fluor 488-conjugated anti-rabbit IgG (Invitrogen, A-11034), 4-HNE (Abcam, ab46545) and Ki67 (Abcam, ab15580). Cell viability and colony formation assay Cell viability was determined by a CCK-8 assay according to the manufacturer’s instructions. The IC50 value was calculated via nonlinear regression fitting. For the colony formation assay, cells were seeded in 6-well plates at a density of 1000 cells per well. The colonies were fixed, stained and counted. SYTOX green nucleic acid staining and immunofluorescence Cells were seeded in a 12-well plate at 40% confluence and treated with DMSO, 100 µM Tasimelteon, or 200 µM Tasimelteon for 48 h. After washing with HBSS, cells were incubated with SYTOX Green (167 nM) for 30 min in the dark. Bright-field and fluorescence images were acquired using a fluorescence microscope. For immunofluorescence, cells on coverslips in a 12-well plate were treated with the same condition, fixed, permeabilized and incubated with anti-Ki67 or 4-HNE primary antibodies and fluorescent secondary antibodies as described previously [28]. Fluorescence images were captured using a fluorescence microscope. BODIPY 581/591 C11 staining Cells in a 20-mm confocal dish were treated with DMSO, 200 µM Tasimelteon with/without 4 µM Fer-1. BODIPY 581/591 C11 was dissolved in 20 µl DMSO. Prior to staining, cells were first washed twice with HBSS, followed by incubation with the probe diluted 1:1000 in HBSS at 37 °C in the dark for 30 min. Cells were then washed twice with HBSS, replenished with pre-warmed HBSS, and immediately subjected to live-cell imaging. Live-cell imaging was performed using a laser scanning confocal microscope (Zeiss, LSM 900 with Airyscan 2). The oxidized form of BODIPY 581/591 C11 was detected in the green channel (Ex: 488 nm; Em: 510–550 nm), and the non-oxidized form was detected in the red channel (Ex: 561 nm; Em: 600–630 nm). Nuclei were stained with Hoechst (Beyotime, C1027) and detected in the DAPI channel. Apoptosis detection Cells in a 10-cm dish were treated with DMSO, 100 µM or 200 µM Tasimelteon, or 10 µM Doxorubicin for 48 h, then harvested and resuspended in binding buffer, stained with Annexin V-FITC and PI for 15 min. Apoptotic cells were analyzed by flow cytometry within 1 h. cAMP assay and intracellular calcium detection LN229 and A172 cells were pretreated with MT1 receptor antagonist S26131 or MT2 receptor antagonist 4-P-PDOT at 0, 0.1, 1, 10, 100 µM for 2 h, and co-cultured with 40 µM melatonin for 48 h. cAMP concentration was measured by ELISA while Ca2+ level was reflected by fluorescence intensity of Fluo-4 AM measured by flow cytometry. Transmission electron microscopy (TEM) Cells were washed and immediately fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer for at least 2 h. Cells were then collected by centrifugation (≤ 3000 rpm, 2 min) and post-fixed with fresh electron microscopy fixative in the dark for 30 min. Samples were rinsed three times with 0.1 M phosphate buffer (3 min each), followed by dehydration, embedding, and polymerization. Ultrathin sections (~ 70 nm) were stained with 2% uranyl acetate and lead citrate, then examined using a JEOL JEM-1230 TEM at 80 kV. Quantification of ROS and MDA levels Cells were incubated with DCFH-DA (10 µM) in serum-free medium for 30 min. After washing, fluorescence was measured by flow cytometry. For MDA assay, cells were lysed, and absorbance was measured to quantify MDA level according to the manufacturer’s instructions. RT-PCR Total RNA was extracted from cells using Trizol reagent (Invitrogen, 15596018CN). Cells in 6 cm dishes were lysed with 500 µL Trizol per dish. After adding chloroform and shaking, samples were centrifuged to separate phases. The aqueous phase was collected, and RNA was precipitated with isopropanol at -80℃. The RNA pellet was washed with 75% ethanol, dried, dissolved in RNase-free water, and quantified spectrophotometrically. Then, 1 µg of total RNA was reverse-transcribed into cDNA using the RT SuperMix for qPCR (Vazyme, R323). Quantitative real-time PCR was performed using a SYBR qPCR Master Mix (Vazyme, Q711) on a real-time PCR system. Each 20 µL reaction contained 10 µL of 2× SYBR Green Master Mix, 0.4 µL of forward primer (10 µM), 0.4 µL of reverse primer (10 µM), 1 µL of cDNA template, and 8.2 µL of nuclease-free water. The thermal cycling conditions were 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s and 60 °C for 30 s. The primer sequences were as follows: ACSL4 (forward: AAGTAGACCAAGCCTTCAG, reverse: GTCCCAGTCCAGGTATTTTTC), SP1 (forward: AGGCTGTGGAAAGTTGTATG, reverse: TGTACGTTTGGGCTCTGTGA), and GAPDH (forward: AATCCCATCACCATCTTCCA, reverse: AAATGAGCCCCAGCCTTCC). The relative expression levels of target genes were calculated using the 2−ΔΔCt method with GAPDH as the internal control. Luciferase assay The firefly luciferase reporter plasmid was generated by inserting the SP1 binding sequence (− GGGGCGGGCG−) upstream of the promoter region in the pGL3-Basic vector was co-transfected with SP1 overexpression plasmid, and the Renilla luciferase plasmid pRL-TK into LN229 and A172 cells. After 24 h, luciferase activity was measured using the Dual-Luciferase® Reporter Assay System, and firefly luciferase activity was normalized to Renilla luciferase. In vivo animal experiment LN229-Luc cells were intracranially injected into the right striatum of nude mice to establish orthotopic glioma models. Mice were randomly assigned to receive PBS or Tasimelteon (50 or 100 mg/kg) via intraperitoneal injection every three days for 21 days. Tumor growth was monitored by bioluminescence imaging, and body weight and general health were recorded to assess treatment tolerance. At the end of treatment, mice were euthanized, and tumor tissues were collected for further analysis. All animal procedures were conducted in accordance with institutional guidelines for animal care and use. Western blotting, histological and immunohistochemistry analysis Cells or tissues were lysed in RIPA buffer supplemented with protease and phosphatase inhibitors, and the lysates were clarified by centrifugation at 12,000 × g for 15 min at 4 °C. Protein concentrations were quantified using a BCA assay kit. Equal amounts of protein were subjected to SDS – PAGE and transferred onto PVDF membranes. After blocking with 5% non-fat milk, the membranes were incubated with the indicated primary antibodies overnight at 4 °C and then with HRP-conjugated secondary antibodies for 1 h at room temperature. Protein bands were visualized using an enhanced chemiluminescence reagent (Thermo, 32106). All the protein samples were processed for immunoblotting analysis as previously described [29]. On the 21st day after tumor inoculation, the hearts, livers, spleens, lungs, kidneys and brains of the nude mice were collected, fixed, embedded in paraffin and sectioned. Immunohistochemistry and hematoxylin and eosin (H&E) staining were performed to evaluate drug efficacy and toxicity. Statistics Statistical analyses were conducted using SPSS version 23.0. Two groups were assessed via t-test, while comparisons among multiple groups were evaluated using one-way ANOVA with post-hoc tests. p < 0.05 was considered statistically significant. Data are presented as mean ± SD. Graphs were created using GraphPad Prism 8.0.1. Results Tasimelteon Inhibits the Proliferation of Glioma Cells To explore whether Tasimelteon has an inhibitory effect on gliomas, cell viability was detected through the CCK-8 assay. In glioma cell lines LN229, A172 and GBM1492 primary glioma cells, cell viability gradually decreased with increasing doses of Tasimelteon. Furthermore, as treatment duration extended, a progressive decline in cell viability was noted (Fig. 1A-C), indicating that Tasimelteon significantly inhibits glioma cell viability in a time- and dose-dependent manner. Notably, Tasimelteon’s effect was more profound in glioma cell lines than HMC, hinting at a potential preferential inhibition of tumor cells over normal glial cells (Fig. 1D). Tasimelteon inhibits viability, colony formation, and proliferation capability of glioma cells. (A-D) Glioma cell lines (LN229 and A172), primary glioma cells (GBM1492), and human microglial cells (HMC) were treated with Tasimelteon at various concentrations (0, 25, 50, 100, 200 µM) for 24, 48, and 72 h. Cell viability was measured using the CCK-8 assay. (E, F) LN229, A172 and HMC cells were treated with DMSO or 100 µM and 200 µM Tasimelteon and cultured for 2 weeks. The number of colonies formed was counted. (G-I) The expression of Ki67, after being treated with Tasimelteon for 48 h, was observed using an inverted fluorescence microscope. The scale bar is 200 μm. Data is presented as mean ± S.D. and analyzed by Student’s t-test or one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001 To clarify whether Tasimelteon inhibits glioma cells proliferation, colony formation and Ki67 staining assays were employed. Tasimelteon treatment significantly reduced the number of colonies of A172 and LN229 cells, with higher concentrations producing more pronounced inhibition; In contrast, treatment with Tasimelteon did not significantly alter the colony formation ability of HMC cells. (Fig. 1E and F). Furthermore, treatment with 200 µM Tasimelteon significantly inhibited the Ki67 positive staining rate of LN229 and A172 cells, indicating that Tasimelteon suppressed the proliferative capacity of glioma cells (Fig. 1G-I). Tasimelteon induces ferroptosis in glioma cells To ascertain whether Tasimelteon induces cell death, we utilized immunofluorescence to examine nucleic acid staining. As shown in Fig. 2A and B, compared to the DMSO-treated control, the positive staining rate significantly increased in LN229 and A172 cells treated with Tasimelteon for 48 h in a dose-dependent manner, suggesting that Tasimelteon promotes glioma cell death. Next, flow cytometry was employed to detect apoptosis (with DOX as a positive control). Treatment of LN229 or A172 cells with 100 µM and 200 µM Tasimelteon did not significantly increase the number of cells in early apoptosis, late apoptosis, or death phases, indicating that Tasimelteon did not induce apoptosis (Fig. 2C and D). Tasimelteon induces ferroptosis in glioma cells. (A, B) Dead cells were analyzed using the SYTOX Green reagent kit. Green indicates dead cells. The scale bar is 100 μm. The number of dead cells was recorded. (C, D) Glioma cell death caused by Tasimelteon is non-apoptotic and was detected using flow cytometry. (E, F) Inhibitor recovery experiment. The ferroptosis inhibitor Lip-1, rather than other cell death inhibitors, can restore the Tasimelteon-induced decrease in glioma cell viability. (G, H) The ROS levels were examined using flow cytometry in the indicated groups. Tasimelteon treatment increases ROS levels in glioma cells. (I) Increased MDA contents were observed in GBM cells treated with increasing concentrations of Tasimelteon. (J, K) Expression of 4-HNE treated with Tasimelteon for 48 h was determined using an inverted fluorescence microscope. The fluorescence intensity was recorded. The scale bar is 200 μm. (L, M) The fluorescence intensities of the reduced and oxidized forms of the BODIPY 581/591 C11 probe were detected using a confocal microscopy in GBM cells treated with Tasimelteon alone or in combination with the ferroptosis inhibitor Fer-1 for 48 h. The scale bar is 40 μm. (N) The TEM images display mitochondrial damages caused by Tasimelteon. Normal mitochondria are indicated by yellow arrows, while damaged mitochondria are indicated by red arrows. The scale bar measures 0.5 μm. The data is presented as mean ± S.D. and analyzed by Student’s t-test or one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001 We then pretreated glioma cells with multiple inhibitors, including ferroptosis inhibitors Fer-1 (4 µM) and Lip-1 (0.1 µM), necrosis inhibitor Nec-1 (10 µM), apoptosis inhibitor Z-VAD (25 µM), autophagy inhibitor CQ-1 (10 µM), and mitochondrial fission inhibitor Mdivi-1 (20 µM). As displayed in Fig. 2E and F, pretreatment with ferroptosis inhibitors weakened the inhibitory effect of Tasimelteon, with Lip-1 showing a particularly significant attenuating effect. In contrast, cell viability remained stable following pretreatment with other inhibitors. These results indicate that ferroptosis, especially excessive lipid peroxidation, is likely a pathway for glioma death caused by Tasimelteon, as Fer-1 prevents membrane lipid damage, while Lip-1 mainly inhibits mitochondrial lipid peroxidation. Furthermore, DCFH-DA, a ROS probe, showed that Tasimelteon obviously increased intracellular ROS accumulation (Fig. 2G and H). Consistently, the levels of MDA and 4-HNE, two well-established markers of lipid peroxidation, were also markedly elevated in Tasimelteon-treated cells compared to the control group (Fig. 2I and K). To further validate lipid peroxidation in Tasimelteon-treated GBM cells, we employed the lipid hydroperoxide probe BODIPY 581/591 C11. Confocal microscopy revealed a significant increase in green fluorescence intensity in Tasimelteon-treated cells, which was markedly reversed by co-treatment with the ferroptosis inhibitor Fer-1, confirming that Tasimelteon promotes ferroptosis-associated lipid peroxidation (Fig. 2L and M). The results of TEM revealed reduced mitochondrial size and a decreased number of mitochondrial cristae in Tasimelteon-treated cells — characteristic morphological hallmarks of ferroptosis, which were comparable to those observed in the Erastin-treated positive control group (Fig. 2N). Altogether, these data demonstrate that Tasimelteon induces ferroptosis by increasing lipid peroxidation in glioma cells. ACSL4 participates in the ferroptosis process triggered by Tasimelteon To investigate the mechanism by which Tasimelteon induces ferroptosis, we examined protein levels related to lipid metabolism, iron metabolism, and the antioxidant system in LN229 and A172 cells. Following Tasimelteon treatment, ACSL4 expression showed a remarkable increase in both cell lines (Fig. 3A), while other proteins displayed no significant changes or consistent trends, suggesting that Tasimelteon may have differential regulatory effects on iron metabolism and antioxidant responses across different cell lines. Further experiments showed that the upregulation of ACSL4 by Tasimelteon was both dose-dependent and stable over time (24 h, 48 h, and 72 h; Fig. 3B). Tasimelteon induces ferroptosis by increasing the expression of ACSL4 in glioma cells. (A) Immunoblotting analysis of key ferroptosis protein levels in glioma cells. The expression level of ACSL4 increases with higher concentrations of Tasimelteon. (B) Western Blotting experiment used to detect ACSL4 expression levels. Tasimelteon changes the level of ACSL4 in glioma cells in a time- and concentration-dependent manner. (C) Immunoblotting analysis of ACSL4 levels in glioma cells. Transient knockdown transfection of ACSL4 in LN229 and A172 cells was efficient. Tasimelteon can restore the decrease in ACSL4 expression caused by siACSL4. (D) Cell viability analyses. Tasimelteon can reverse the increased levels of cell viability caused by siACSL4 using a CCK-8 kit. (E) Clone formation experiment. Tasimelteon-induced reduction in colony formation can be reversed by siACSL4. (F) The depressed MDA contents caused by siACSL4 can be reversed by Tasimelteon. (G) The decreased levels of ROS were examined using flow cytometry, and it was found that siACSL4 reversed this effect, which was further reversed by Tasimelteon. The data is presented as mean ± S.D. and analyzed by Student’s t-test or one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001 To further elucidate the role of ACSL4 in Tasimelteon-induced ferroptosis, we conducted knockdown experiments using two different siRNAs. While Tasimelteon significantly upregulated ACSL4 in the control groups, ACSL4 knockdown partially impaired the upregulation (Fig. 3C). Crucially, ACSL4 knockdown significantly rescued the decrease in cell viability and colony formation in LN229 and A172 cells exposed to Tasimelteon (Fig. 3D and E). Additionally, cellular MDA and ROS levels were dramatically reduced upon ACSL4 knockdown (Fig. 3F and G). These findings collectively indicate that ACSL4 plays a pivotal role in the Tasimelteon-mediated ferroptosis of glioma cells. SP1 binding to ACSL4 promoter dominates ferroptosis behavior in glioma cells by Tasimelteon To explore how Tasimelteon regulates ACSL4, we first determined mRNA levels in treated glioma cells, observing a gradient increase in ACSL4 at the transcriptional level (Fig. 4A). Potential factors (SP1, STAT1, ETS1, RELA) were screened from transcription factor databases (Fig. 4B). Given that ACSL4 can be regulated by several factors such as SP1, A20, SHP2, and YAP [30], we examined their protein levels in LN229 and A172 cells exposed to Tasimelteon. SP1 expression was significantly upregulated, while others showed no consistent trends (Fig. 4C). The JASPAR database predicted that SP1 potentially binds to the ACSL4 promoter (Fig. 4D). To verify this, we constructed a firefly luciferase reporter plasmid (Fluc-insert) by inserting the binding site -GGGGCGGGCG- before the promoter region. Dual-luciferase assays showed that relative fluorescence was significantly higher in Fluc-insert transfected cells, and Tasimelteon treatment further amplified this luciferase activity (Fig. 4E), confirming that SP1 binds to the ACSL4 promoter and that Tasimelteon enhances this binding capability. SP1 regulates ACSL4 expression by binding to its promoter under Tasimelteon treatment. (A) qPCR analysis of ACSL4 mRNA levels in LN229 and A172 cells treated with 0, 100, or 200 µM Tasimelteon for 48 h. (B) Transcription factors predicted to bind the ACSL4 promoter (SP1, STAT1, ETS1, RELA) were identified via various transcription factor databases (JASPAR, KnockTF, hTFtarget). (C) Western blot analysis of SP1, STAT1, RELA, ETS1, A20, SHP2, YAP, and ACSL4 protein levels in LN229 and A172 cells treated with 0, 100, or 200 µM Tasimelteon for 48 h. (D) SP1 binding to the ACSL4 promoter was predicted using the JASPAR database. (E) Dual-luciferase reporter assays confirmed SP1 binding to the ACSL4 promoter in LN229 and A172 cells following Tasimelteon treatment. (F) Western blot detection of SP1 and ACSL4 protein levels in LN229 and A172 cells after six different treatment conditions, including SP1 overexpression and ACSL4 mutation. (G) Colony formation assays were conducted to assess proliferation capacity under the same six treatment conditions. (H) MDA levels were measured using a lipid peroxidation assay kit across the six groups. (I) ROS levels were evaluated by flow cytometry in LN229 and A172 cells under the same six conditions. * p < 0.05, ** p < 0.01, *** p < 0.001 To reinforce these findings, we compared the effects of wild-type ACSL4 (ACSL4-WT) and a mutant lacking SP1 binding capability (ACSL4-Mut). ACSL4-Mut significantly lessened the upregulation of ACSL4 by Tasimelteon, further elucidating that Tasimelteon activates ACSL4 transcription by promoting SP1 binding (Fig. 4F). Furthermore, while overexpression of ACSL4-WT reduced colony number and size—an effect further enhanced by Tasimelteon—the ACSL4-Mut failed to exert a similar inhibitory effect (Fig. 4G). Similarly, MDA and ROS levels were elevated in ACSL4-WT overexpressed cells, whereas ACSL4-Mut showed no significant increase (Fig. 4H and I). Overall, these results underscore the critical role of SP1 binding to the ACSL4 promoter in mediating Tasimelteon’s effects, including the suppression of proliferation and induction of lipid peroxidation. Gln 465 and Leu 467 are crucial for the binding of tasimelteon to SP1 Interestingly, Tasimelteon did not significantly alter SP1 mRNA levels (Fig. 5A), but instead stabilized SP1 protein expression in both LN229 and A172 cells (Fig. 5B). A molecular docking model showed that Tasimelteon could combine with SP1 amino acid residues through hydrogen bonding, with binding energy of -6.1 kcal/mol (Fig. 5C), revealing that Tasimelteon binds to glutamine 465 (Q465) and leucine 467 (L467) of SP1 to stabilize its protein structure and expression. Tasimelteon stabilizes SP1 protein by directly binding to specific amino acid residues. (A) qPCR analysis showing SP1 mRNA levels in LN229 and A172 cells treated with 0, 100, or 200 µM Tasimelteon for 48 h. (B) Western blot analysis of SP1 protein degradation in cells pretreated with 200 µM Tasimelteon or DMSO for 42 h, followed by 0, 2, 4, 6, or 8 h of cycloheximide (CHX, 20 µg/mL) exposure. (C) Molecular docking using AutoDock Vina predicts Tasimelteon binding to SP1 at Gln465 and Leu467. (D) Western blot showing SP1 and Flag levels in LN229 and A172 cells transfected with SP1-WT, Q465N, L467V, or double mutant (Mut) plasmids after 24 h Tasimelteon treatment and CHX time-course (0–6 h). (E) Expression of ACSL4, SP1, and Flag in cells transfected with vector, SP1-WT, Q465N, L467V, or Mut plasmids following 24 h Tasimelteon exposure. (F) ROS accumulation assessed by flow cytometry in the same treatment groups. (G) MDA levels measured in LN229 and A172 cells under the five treatment conditions using a lipid peroxidation assay. (H) Colony formation assay evaluating the proliferative capacity of cells under the five conditions described above. * p < 0.05, ** p < 0.01, *** p < 0.001 To test this hypothesis, Flag-tagged point mutations (SP1-Q465N, SP1-L467V) and a double mutation (SP1-Q465N/L467V) were constructed. Upon Tasimelteon treatment, cells transfected with these mutations showed a distinct decrease in SP1 protein stability compared to cells transfected with SP1-wildtype (WT) (Fig. 5D). Furthermore, these three mutations partially inhibited the Tasimelteon-induced upregulation of ACSL4 (Fig. 5E). Correspondingly, lipid peroxidation and ROS levels were suppressed in the mutant groups compared to SP1-WT-overexpressing cells (Fig. 5F and G). Finally, SP1 mutants overexpression markedly weakened the inhibitory effect of Tasimelteon on cell proliferative capacity (Fig. 5H). These results confirm that Gln 465 and Leu 467 of SP1 are crucial for the binding of Tasimelteon and the subsequent induction of ferroptosis-related behaviors in glioma cells. Tasimelteon triggers ferroptosis in glioma cells without requiring MT1/MT2 activation Next, we wondered if Tasimelteon-triggered ferroptosis was associated with its receptor’s activation. Activation of MT1 mainly decreases intracellular cAMP levels, whereas MT2 activation causes calcium influx [31]. To determine the dosage of agonists, 40 µM Melatonin-treated LN229 and A172 cells were exposed to inhibitor of MT1-S26131 or MT2-4-P-PDOT with different concentration gradients to detect intracellular cAMP or Ca2+ concentration, respectively (Fig. 6A and B). As shown in Fig. 6C and D, Tasimelteon significantly reduced cAMP content and increased Ca2+ concentration in the two glioma cell lines. Given that Ca2+ influx may cause calcium overload and subsequently induce oxidative stress, we next examined whether the increase in ROS induced by Tasimelteon was Ca2+-dependent. After treatment with the calcium chelator BAPTA-AM (10 µM), ROS levels in 200 µM Tasimelteon-treated glioma cells were not significantly reduced (Figure S1A and S1B), indicating that the oxidative stress triggered by Tasimelteon is likely independent of Ca2+ influx [32]. This phenomenon was reversed with 10 µM S26131, 10 µM 4-P-PDOT and both pretreatment for 2 h, indicating that 200 µM Tasimelteon activated MT1 and MT2 in glioma cells. However, the same treatment did not cause protein level increase in SP1 or ACSL4 in Tasimelteon-treated cells (Fig. 6E). Moreover, the cellular MDA in LN229 or A172 cells exposure to Tasimelteon displayed almost no difference between groups with or without the two inhibitors treatment (Fig. 6F). Similar results were observed in ROS detection (Fig. 6G). Additionally, S26131, 4-P-PDOT, or even a combination of the two failed to rescue the Tasimelteon-induced growth inhibition (Fig. 6H). Taken together, our data suggest that MT1/MT2 was not involved in Tasimelteon-induced ferroptosis. Tasimelteon-induced ferroptosis occurs independently of MT1 and MT2 receptor activation. (A) cAMP levels in LN229 and A172 cells after treatment with increasing concentrations of the MT1 antagonist S26131. (B) Intracellular free Ca²⁺ levels in LN229 and A172 cells after treatment with increasing concentrations of the MT2 antagonist 4-P-PDOT. (C) Intracellular cAMP and (D) free Ca²⁺ levels were measured in LN229 and A172 cells treated with 200 µM Tasimelteon or DMSO for 48 h. (E) Cells were pretreated for 2 h with the MT1 receptor antagonist S26131 (10 µM), MT2 receptor antagonist 4-P-PDOT (10 µM), or both, followed by 48 h Tasimelteon treatment. Western blot analysis was used to detect SP1 and ACSL4 protein levels in LN229 and A172 cells under five different conditions. (F) MDA levels were assessed using a lipid peroxidation assay kit in all treatment groups. (G) ROS levels were detected by flow cytometry in LN229 and A172 cells subjected to the same five treatments. (H) Colony formation assays were performed to evaluate the effect of MT1/MT2 blockade on Tasimelteon-induced growth inhibition in glioma cells. * p < 0.05, ** p < 0.01, *** p < 0.001 Tasimelteon suppresses tumor growth in vivo An orthotopic glioma-bearing nude mice model was established with LN229-Luc cells. Mice were randomly divided into 3 groups and treated with PBS or Tasimelteon at 50 mg/kg and 100 mg/kg, administered intraperitoneal injection over 21 days. Tasimelteon significantly inhibited tumor growth compared to the control group, with the higher dose (100 mg/kg) showing the most pronounced effect (Fig. 7A). H&E staining confirmed substantial reduction in tumor size in the Tasimelteon-treated groups compared to the PBS control (Fig. 7B). In addition, survival curves revealed that Tasimelteon treatment prolonged the lifespan of the glioma-bearing mice, with a more prominent extension observed at the 100 mg/kg dose (Fig. 7C). Weight tracking indicated that Tasimelteon treatment obviously delayed weight loss associated with tumor burden, suggesting a protective effect on the overall health of the mice (Fig. 7D). Noteworthy, Tasimelteon did not cause observable damage to vital organs (heart, liver, spleen, lungs, and kidneys) from the treated mice, as shown by H&E staining (Fig. 7E). Together, these results suggested that Tasimelteon not only effectively inhibits glioma growth in vivo but also improves survival without causing toxicity. Tasimelteon inhibits tumor growth in vivo. (A) Luminescence images of orthotopic glioma-bearing nude mice at days 7, 14, and 21 treated with Tasimelteon (50 mg/kg, 100 mg/kg) or PBS administered by intraperitoneal injection. Tasimelteon treatments significantly inhibited tumor growth. n = 5 mice. (B) H&E staining showed Tasimelteon treatment inhibited tumor growth in mice brains. n = 5 mice. (C) Survival rates of mice. Tasimelteon extended lifespan in mice. n = 5 mice. (D) Changes in mouse weights. Tasimelteon treatment significantly delayed weight decrease in mice. n = 5 mice. (E) H&E staining shows Tasimelteon treatment has no damaging effect on mice’s heart, liver, spleen, lungs, and kidneys. The data is presented as mean ± S.D. and analyzed by Student’s t-test or one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001 Tasimelteon causes ferroptosis in glioma-bearing mice Immunohistochemistry analysis showed that Tasimelteon treatment led to a dose-dependent reduction in Ki67 expression, while simultaneously increasing the expression of ACSL4 and SP1 (Fig. 8A-D). Tasimelteon significantly elevated SP1 and ACSL4 levels in tumor tissues from treated mice, supporting the immunohistochemistry findings (Fig. 8E-G). Moreover, biochemical assays revealed that increased MDA and ROS levels in the tumor tissues, both of which are hallmarks of ferroptosis (Fig. 8H and I). Finally, TEM images showed structural changes in the mitochondria of tumor tissue from Tasimelteon-treated mice, including reduced cristae and other signs of mitochondrial damage (Fig. 8J). Tasimelteon induces ferroptosis in tumor cells of tumor-bearing mice. (A-D) ACSL4 and SP1 expression were performed using an immunohistochemistry experiment. Scale bar = 200 μm. The average optical density value of Ki67, ACSL4, and SP1 staining cells in the LN229-Luc glioma xenografts was measured. (E-G) Immunoblotting analysis of SP1 and ACSL4 levels in tumor tissues from tumorigenic mice. SP1 and ACSL4 were significantly increased in tumor tissues of mice treated with Tasimelteon. n = 3 mice. (H) The MDA content in tumor tissues was elevated in Tasimelteon-treated mice. n = 5 mice. (I) Variations of ROS in tumor tissues. (J) TEM images of mitochondria in tumor tissues from mice treated with PBS or Tasimelteon. Yellow arrows indicate normal mitochondria and red arrows indicate damaged mitochondria. Scale bar = 0.5 μm. The data is presented as mean ± S.D. and analyzed by Student’s t-test or one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001 Discussion This study provides the first comprehensive evidence that Tasimelteon, a clinically approved melatonin receptor agonist, exerts potent anti-glioma activity by inducing ferroptosis. Through both in vitro and in vivo experiments, we demonstrate that Tasimelteon significantly inhibits glioma cell proliferation in a time- and dose-dependent manner. Mechanistically, Tasimelteon promotes ferroptotic cell death by enhancing lipid peroxidation and increasing intracellular ROS levels, accompanied by mitochondrial damage characteristic of ferroptosis. Importantly, we identify SP1 as a direct molecular target of Tasimelteon. Tasimelteon stabilizes SP1 protein by binding to specific residues (Gln465 and Leu467), thereby enhancing SP1’s transcriptional activation of ACSL4, a key driver of ferroptosis. These effects occur independently of MT1/MT2 receptor signaling, revealing a receptor-independent mechanism. Previous studies have shown that melatonin exerts anti-tumor effects through antioxidant activity, modulation of calmodulin signaling, inhibition of angiogenesis, and estrogen receptor blockade [33–35]. However, its clinical application in oncology remains limited by blood-brain barrier permeability, short half-life, and endocrine side effects [36]. Tasimelteon was originally developed for sleep disorders, yet its anti-tumor potential was unexplored [14]. In our study, we demonstrate that Tasimelteon induces ferroptosis in glioma cells by activating the ACSL4 signaling pathway, a mechanism distinct from melatonin’s previously reported anti-proliferative pathways (Fig. 9). Notably, this occurs independently of MT1/MT2 receptor activation, highlighting a novel receptor-independent mechanism of action for melatonin receptor agonists in cancer therapy. Tasimelteon’s improved pharmacokinetics may overcome the translational limitations of melatonin in oncology [16]. The mechanism of Tasimelteon-induced ferroptosis in glioma cells. Tasimelteon inhibits glioblastoma by directly binding to the transcription factor SP1 at Gln465 and Leu467 residues, which upregulates ACSL4 gene expression. Elevated ACSL4 promotes polyunsaturated fatty acid (PUFA) metabolism, leading to lipid peroxide accumulation and ferroptosis induction, ultimately causing GBM cell death through this iron-dependent mechanism. This figure was created with https://BioRender.com Ferroptosis has gained considerable attention as a novel strategy in cancer therapy, particularly due to its distinct mechanism of inducing regulated cell death through iron-dependent lipid peroxidation, which bypasses many of the resistance pathways associated with conventional apoptosis-based treatments [37]. Compounds such as Erastin, RSL3, and FIN56, despite showing strong ferroptotic activity in vitro. However, these ferroptosis inducers are beset by critical pharmacological limitations: Erastin undergoes rapid metabolic degradation and exhibits poor aqueous solubility [38], while RSL3 and FIN56 display suboptimal pharmacokinetic profiles and dose-dependent cytotoxicity, factors that narrow their therapeutic windows and fundamentally limit their potential in combinatorial treatment strategies [39, 40]. Many of these agents have not progressed beyond the preclinical stage, and their application in brain tumors is further restricted by their inability to efficiently cross the blood-brain barrier [41], a critical challenge given the highly selective nature of this anatomical boundary. In contrast, Tasimelteon is a clinically approved melatonin receptor agonist with an established safety profile validated through extensive clinical trials. Unlike melatonin, Tasimelteon exhibits several improved pharmacological properties, including a longer plasma half-life, enhanced oral absorption, greater receptor selectivity, and a markedly lower propensity for endocrine disruption. It has demonstrated reliable permeability of central nervous system, with the capacity to effectively penetrate both the blood-brain barrier (BBB) and the blood-tumor barrier (BTB), making Tasimelteon a viable candidate for targeting brain tumors such as glioma [42, 43]. These advantages position Tasimelteon as a highly practical candidate for repurposing in glioma treatment, where effective, BBB-penetrant, and well-tolerated therapeutic options remain critically limited. Nevertheless, although our findings support the involvement of the SP1/ACSL4 axis in Tasimelteon-induced ferroptosis, the upstream regulatory events linking Tasimelteon treatment to oxidative stress and ferroptotic activation require further clarification. In addition, the broader applicability of this mechanism across different glioma contexts warrants further investigation. Conclusions This study is the first to demonstrate the inhibitory effects of Tasimelteon on glioma, offering a novel perspective on its therapeutic potential. Given the urgent need for effective therapies, this research may help overcome current clinical limitations. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements The authors would like to thank all members of Professor Piao Lab. Abbreviations 4-Hydroxynonenal Acyl-CoA synthetase long chain family member 4 American Type Culture Collection Bicinchoninic acid assay Butylated hydroxytoluene Bovine serum albumin cyclic adenosine monophosphate Cell counting kit-8 4’,6-diamidino-2-phenylindole 2’,7’-dichlorodihydrofluorescein diacetate Dihydroorotate dehydrogenase Divalent metal transporter 1 E26 transformation-specific sequence 1 Fluo-4 acetoxymethyl ester Ferroptosis suppressor protein 1 Ferritin heavy chain 1 Glyceraldehyde-3-phosphate dehydrogenase Glioblastoma multiforme Glutathione peroxidase 4 Hypoxia-inducible factor 1-alpha Human microglia cells Lipid alcohol Lipid hydroperoxide ipid reactive oxygen species Malondialdehyde Melatonin receptor 1 Melatonin receptor 2 Reduced nicotinamide adenine dinucleotide Nuclear receptor coactivator 4 Nuclear factor erythroid 2-related factor 2 Reactive oxygen species RAS-selective lethal small molecule 3 Src homology 2 domain-containing phosphatase 2 Solute carrier family 7 member 11 Specificity protein 1 Signal transducer and activator of transcription 1 Transmission electron microscopy Transferrin receptor Yes-associated protein Author contributions Yi Chen: Writing - original draft, Visualization, Validation, Methodology, Investigation, Formal analysis, Data curation. Jicheng Li: Visualization, Validation, Data curation. Huilan Yang: Validation, Data curation. Haiyang Liang: Validation, Data curation. Ji Shi: Validation, Data curation. Quan Li: Validation, Data curation. Qiang Liu: Validation, Data curation. Jia Liu: Validation, Data curation. Xuanming Zhang: Validation, Data curation. Huizhe Xu: Writing - review & editing, Supervision, Funding acquisition. Haozhe Piao: Writing - review & editing, Writing - original draft, Supervision, Investigation, Funding acquisition, Formal analysis, Data curation. Funding This work was supported by grants from the National Natural Science Foundation of China (82203682 and 82302980), Applied Basic Research Program of Science and Technology of Liaoning Province (No. 2025JH2/101330061), Key Project of Department of Science and Technology of Liaoning Province (No. 2025JH2/101800106). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All procedures that involved animals were approved by the experimental animal ethics committee: China Medical University (CMUXN2023491). All surgery was performed under isoflurane anesthesia, and all efforts were made to minimize suffering. Consent for publication N/A. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yi Chen, Jicheng Li, Huilan Yang and Haiyang Liang contributed equally to this work. Contributor Information Huizhe Xu, Email: xuhuizhe@cancerhosp-ln-cmu.com. Haozhe Piao, Email: piaohaozhe@cancerhosp-ln-cmu.com. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement No datasets were generated or analysed during the current study.